Clinical results of patients with locally advanced breast cancer managed with neoadjuvant chemotherapy and received adjuvant hormonal therapy at the National Cancer Institute (INC).

Desenlaces clínicos de una cohorte de pacientes con cáncer de mama localmente avanzado manejadas con terapia hormonal adyuvante en el Instituto Nacional de Cancerología (INC).

Background: For Colombia, according to Globocan 2018 data, breast cancer is the most common type of cancer in women with 13.380 cases representing 24.8% of all cases. Objective: Describe the disease-free survival and overall survival of patients with locally advanced breast cancer managed with neoadjuvant chemotherapy at the National Cancer Institute (INC) (Bogotá, Colombia) during 2012 to 2014 and received adjuvant hormonal therapy as part of their treatment. Methods: This is an observational descriptive retrospective study. The sample was for convenience of patients with locally advanced breast cancer who were managed with adjuvant hormonal therapy. Results: 77 patients were included. The median follow-up was 4.6 years. The average age was 53 years. The most of patients were classified in clinical stage IIIB (51.9%, n=40) and the most common tumor biological subtype was luminal B HER2 negative 45.5% (n=35). The total recurrence frequency (local, regional and systemic) was 16.9% (n=13). The most used adjuvant hormonal treatment was switch therapy 40.3% (n=31) of the cases. No differences were found in disease-free and overall survival when the biological tumor subtype and the type of adjuvant hormonal treatment received, regarding the safety profile, the treatment administered was quite safe, the most frequent toxicity being arthralgias 11.7% (n=9) and osteoporosis 10.4% (n=8). Conclusions: The median disease-free and overall survival was 30 months and 45.2 months respectively, no differences were documented between the different biological tumor subtypes and the treatment groups, however at the descriptive level it was observed that luminal a tumors as well as patients who received hormonal therapy with switch scheme had a lower recurrence frequency and better overall survival.